GSK to shift consumer media business by end of Feb.

Share this article:
GSK to shift consumer media business by end of Feb.
GSK to shift consumer media business by end of Feb.
GlaxoSmithKline should be finished transitioning the media planning and buying for its North American OTC business by the end of February, a spokesperson for the drugmaker said. The benefactor of the switch, WPP shop MediaCom, already handles buying and planning tasks for GSK's North American prescription-drug business.

Malesia Dunn, GSK director of communications, said the shift was simply a business decision to allow for greater efficiency.

Media for the OTC brands—which include Panadol, Aquafresh, Lucozade and Nicorette—had been split among MediaCom, Havas' MPG, Publicis' Optimedia and Campbell Mithun.

Notably, last year GSK moved all of its professional advertising business in the opposite direction, from WPP agencies to IPG ones, including Draftfcb Healthcare and Lowe Healthcare's Integrated Communications unit.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...